Prostate carcinoma and radiation therapy: therapeutic treatment resistance and strategies for targeted therapeutic intervention
AuthorsFitzgerald, Thomas J.
Goel, Hira Lal
Stein, Gary S.
Lian, Jane B.
Davis, Roger J.
Doxsey, Stephen J.
Balaji, Kethandapatti C.
Aronowitz, Jesse N.
Languino, Lucia R.
Faculty AdvisorThomas Fitzgerald
UMass Chan AffiliationsSchool of Medicine
Department of Surgery
Department of Cell Biology
Program in Molecular Medicine
Department of Cancer Biology
Department of Radiation Oncology
Male Urogenital Diseases
MetadataShow full item record
AbstractAdenocarcinoma of the prostate remains a significant public health problem and a prevalent cancer in men. Prostate-specific antigen used as a biomarker has established a clear migration of patients towards earlier-stage disease at presentation. However, in spite of process improvements in traditional therapies including surgery, radiation therapy, and hormone management, there remains a significant cohort of patients with intermediate- to high-risk features for poor outcome in spite of optimal use of traditional management. This paper focuses on future treatment strategies integrating new therapeutic options with traditional management, specifically to pinpoint new radiation therapy strategies.
SourceExpert Rev Anticancer Ther. 2008 Jun;8(6):967-74. doi: 10.1586/14737188.8.131.527. Link to article on publisher's site
Permanent Link to this Itemhttp://hdl.handle.net/20.500.14038/49239
Medical student Jiayi Huang participated in this study as part of the Senior Scholars research program at the University of Massachusetts Medical School.
Related ResourcesLink to Article in PubMed